Patents by Inventor Holger Rabe

Holger Rabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of separating lipids from a lysed lipids containing biomass
    Patent number: 11946017
    Abstract: The current invention relates to a method of separating polyunsaturated fatty acids containing lipids from a lipids containing biomass.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: April 2, 2024
    Assignees: Evonik Operations GmbH, DSM IP Assets B.V.
    Inventors: Manfred Bärz, Marc Beiser, Georg Borchers, Stephen Robert Cherinko, Mathias Dernedde, Michael Diehl, Xiao Daniel Dong, Jürgen Haberland, Michael Benjamin Johnson, Robert Cody Kertis, Jochen Lebert, Neil Francis Leininger, Kirt Lyvell Matthews, Sr., Holger Pfeifer, Christian Rabe, Shannon Elizabeth Ethier Resop, Ginger Marie Shank, Vinod Tarwade, David Allen Tinsley, Daniel Verkoeijen
  • Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
    Publication number: 20080114032
    Abstract: The present invention relates to the use of 1-ar(alk)ylimidazolin-2-ones which contain a disubstituted amine radical in the 4-position for the treatment or prevention of central nervous system disorders including depression, anxiety, movement disorders, and especially dystonia, and psychotic disorders, and especially schizophrenia and psychotic symptoms associated to other mental disorders.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 15, 2008
    Inventors: Barbara Langen, Chris Rundfeldt, Rita Dost, Hartmut Luddens, Holger Rabe
  • Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
    Publication number: 20050032863
    Abstract: The present invention relates to the use of 1-ar(alk)ylimidazolin-2-ones which contain a disubstituted amine radical in the 4-position for the treatment or prevention of central nervous system disorders including depression, anxiety, movement disorders, and especially dystonia, and psychotic disorders, and especially schizophrenia and psychotic symptoms associated to other mental disorders.
    Type: Application
    Filed: June 28, 2004
    Publication date: February 10, 2005
    Inventors: Barbara Langen, Chris Rundfeldt, Rita Dost, Hartmut Luddens, Holger Rabe